According to a post on the FDA’s website, PepGen’s treatment of Duchenne Muscular Dystrophy received orphan designation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PEPG:
- PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- PepGen announces clearance of CTA by U.K. MHRA to begin CONNECT2-EDO51
- PepGen Earns FDA Fast Track Status for Myotonic Dystrophy Drug
- PepGen receives U.S. Fast Track designation for PGN-EDODM1
- PepGen Inc. Announces Pricing for Its Offering
